{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T04:42:56Z","timestamp":1793162576577,"version":"4.5.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2023,11,2]],"date-time":"2023-11-02T00:00:00Z","timestamp":1698883200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,11,2]],"date-time":"2023-11-02T00:00:00Z","timestamp":1698883200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1007\/s40262-023-01318-3","type":"journal-article","created":{"date-parts":[[2023,11,2]],"date-time":"2023-11-02T07:02:05Z","timestamp":1698908525000},"page":"1765-1779","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Evolution of Ritlecitinib Population Pharmacokinetic Models During Clinical Drug Development"],"prefix":"10.1007","volume":"62","clinical-trial-number":[{"clinical-trial-number":"nct02309827","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02684760","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02958865","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02969044","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03232905","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03732807","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04016077","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03715829","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04037865","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04004663","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04634565","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02974868","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3302-8742","authenticated-orcid":false,"given":"Jessica","family":"Wojciechowski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivek","family":"S Purohit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeamin","family":"Huh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Banfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Nicholas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,2]]},"reference":[{"issue":"6","key":"1318_CR1","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1021\/acschembio.9b00188","volume":"14","author":"H Xu","year":"2019","unstructured":"Xu H, Jesson MI, Seneviratne UI, Lin TH, Sharif MN, Xue L, et al. PF-06651600, a dual JAK3\/TEC family kinase inhibitor. ACS Chem Biol. 2019;14(6):1235\u201342. https:\/\/doi.org\/10.1021\/acschembio.9b00188.","journal-title":"ACS Chem Biol"},{"issue":"12","key":"1318_CR2","doi-asserted-by":"publisher","first-page":"3442","DOI":"10.1021\/acschembio.6b00677","volume":"11","author":"JB Telliez","year":"2016","unstructured":"Telliez JB, Dowty ME, Wang L, Jussif J, Lin T, Li L, et al. Discovery of a JAK3-selective inhibitor: functional differentiation of JAK3-selective inhibition over pan-JAK or JAK1-selective inhibition. ACS Chem Biol. 2016;11(12):3442\u201351. https:\/\/doi.org\/10.1021\/acschembio.6b00677.","journal-title":"ACS Chem Biol"},{"issue":"2","key":"1318_CR3","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.jaad.2022.11.005","volume":"88","author":"K Ezzedine","year":"2023","unstructured":"Ezzedine K, Peeva E, Yamaguchi Y, Cox LA, Banerjee A, Han G, et al. Efficacy and safety of oral ritlecitinib for the treatment of active nonsegmental vitiligo: a randomized phase 2b clinical trial. J Am Acad Dermatol. 2023;88(2):395\u2013403. https:\/\/doi.org\/10.1016\/j.jaad.2022.11.005.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"1318_CR4","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.jaad.2021.03.050","volume":"85","author":"B King","year":"2021","unstructured":"King B, Guttman-Yassky E, Peeva E, Banerjee A, Sinclair R, Pavel AB, et al. A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results. J Am Acad Dermatol. 2021;85(2):379\u201387. https:\/\/doi.org\/10.1016\/j.jaad.2021.03.050.","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"1318_CR5","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1002\/art.41316","volume":"72","author":"MF Robinson","year":"2020","unstructured":"Robinson MF, Damjanov N, Stamenkovic B, Radunovic G, Kivitz A, Cox L, et al. Efficacy and safety of PF-06651600 (ritlecitinib), a novel JAK3\/TEC inhibitor, in patients with moderate-to-severe rheumatoid arthritis and an inadequate response to methotrexate. Arthritis Rheumatol. 2020;72(10):1621\u201331. https:\/\/doi.org\/10.1002\/art.41316.","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"1318_CR6","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1016\/j.jaci.2021.10.036","volume":"149","author":"E Guttman-Yassky","year":"2022","unstructured":"Guttman-Yassky E, Pavel AB, Diaz A, Zhang N, Del Duca E, Estrada Y, et al. Ritlecitinib and brepocitinib demonstrate significant improvement in scalp alopecia areata biomarkers. J Allergy Clin Immunol. 2022;149(4):1318\u201328. https:\/\/doi.org\/10.1016\/j.jaci.2021.10.036.","journal-title":"J Allergy Clin Immunol"},{"issue":"23","key":"1318_CR7","doi-asserted-by":"publisher","first-page":"00007","DOI":"10.1016\/j.cgh.2022.12.029","volume":"S1542\u20133565","author":"WJ Sandborn","year":"2023","unstructured":"Sandborn WJ, Danese S, Leszczyszyn J, Romatowski J, Altintas E, Peeva E, et al. Oral ritlecitinib and brepocitinib for moderate-to-severe ulcerative colitis: results from a randomized, phase 2b study. Clin Gastroenterol Hepatol. 2023;S1542\u20133565(23):00007\u201311. https:\/\/doi.org\/10.1016\/j.cgh.2022.12.029.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"10387","key":"1318_CR8","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1016\/S0140-6736(23)00222-2","volume":"401","author":"B King","year":"2023","unstructured":"King B, Zhang X, Harcha WG, Szepietowski JC, Shapiro J, Lynde C, et al. Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b\u20133 trial. Lancet. 2023;401(10387):1518\u201329. https:\/\/doi.org\/10.1016\/S0140-6736(23)00222-2.","journal-title":"Lancet"},{"issue":"5","key":"1318_CR9","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1007\/s40262-021-01104-z","volume":"61","author":"J Wojciechowski","year":"2022","unstructured":"Wojciechowski J, Malhotra BK, Wang X, Fostvedt L, Valdez H, Nicholas T. Population pharmacokinetics of abrocitinib in healthy individuals and patients with psoriasis or atopic dermatitis. Clin Pharmacokinet. 2022;61(5):709\u201323. https:\/\/doi.org\/10.1007\/s40262-021-01104-z.","journal-title":"Clin Pharmacokinet"},{"issue":"9","key":"1318_CR10","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1002\/psp4.12838","volume":"11","author":"RJ Svensson","year":"2022","unstructured":"Svensson RJ, Jonsson EN. Efficient and relevant stepwise covariate model building for pharmacometrics. CPT Pharmacometrics Syst Pharmacol. 2022;11(9):1210\u201322. https:\/\/doi.org\/10.1002\/psp4.12838.","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"6","key":"1318_CR11","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1002\/cpdd.471","volume":"7","author":"G Ma","year":"2018","unstructured":"Ma G, Xie R, Strober B, Langley R, Ito K, Krishnaswami S, et al. Pharmacokinetic characteristics of tofacitinib in adult patients with moderate to severe chronic plaque psoriasis. Clin Pharmacol Drug Dev. 2018;7(6):587\u201396. https:\/\/doi.org\/10.1002\/cpdd.471.","journal-title":"Clin Pharmacol Drug Dev."},{"issue":"8","key":"1318_CR12","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1007\/s40262-017-0605-6","volume":"57","author":"B Kl\u00fcnder","year":"2018","unstructured":"Kl\u00fcnder B, Mohamed MF, Othman AA. Population pharmacokinetics of upadacitinib in healthy subjects and subjects with rheumatoid arthritis: analyses of phase I and II clinical trials. Clin Pharmacokinet. 2018;57(8):977\u201388. https:\/\/doi.org\/10.1007\/s40262-017-0605-6.","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"1318_CR13","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1002\/jcph.1550","volume":"60","author":"A Nader","year":"2020","unstructured":"Nader A, Stodtmann S, Friedel A, Mohamed MF, Othman AA. Pharmacokinetics of upadacitinib in healthy subjects and subjects with rheumatoid arthritis, Crohn\u2019s disease, ulcerative colitis, or atopic dermatitis: population analyses of phase 1 and 2 clinical trials. J Clin Pharmacol. 2020;60(4):528\u201339. https:\/\/doi.org\/10.1002\/jcph.1550.","journal-title":"J Clin Pharmacol"},{"issue":"5\u20136","key":"1318_CR14","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1023\/a:1022972420004","volume":"29","author":"PO Gisleskog","year":"2002","unstructured":"Gisleskog PO, Karlsson MO, Beal SL. Use of prior information to stabilize a population data analysis. J Pharmacokinet Pharmacodyn. 2002;29(5\u20136):473\u2013505. https:\/\/doi.org\/10.1023\/a:1022972420004.","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"5","key":"1318_CR15","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s10928-020-09695-z","volume":"47","author":"AHP Chan Kwong","year":"2020","unstructured":"Chan Kwong AHP, Calvier EAM, Fabre D, Gattacceca F, Khier S. Prior information for population pharmacokinetic and pharmacokinetic\/pharmacodynamic analysis: overview and guidance with a focus on the NONMEM PRIOR subroutine. J Pharmacokinet Pharmacodyn. 2020;47(5):431\u201346. https:\/\/doi.org\/10.1007\/s10928-020-09695-z.","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"1318_CR16","unstructured":"R: A language and environment for statistical computing. R Foundation for Statistical Computing. 2019. https:\/\/www.R-project.org\/. Accessed 14 Aug 2023."},{"issue":"7","key":"1318_CR17","doi-asserted-by":"publisher","first-page":"2892","DOI":"10.1128\/AAC.01193-08","volume":"53","author":"K Abduljalil","year":"2009","unstructured":"Abduljalil K, Kinzig M, Bulitta J, Horkovics-Kovats S, S\u00f6rgel F, Rodamer M, et al. Modeling the autoinhibition of clarithromycin metabolism during repeated oral administration. Antimicrob Agents Chemother. 2009;53(7):2892\u2013901. https:\/\/doi.org\/10.1128\/AAC.01193-08.","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"1318_CR18","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1038\/clpt.2008.302","volume":"85","author":"ET Morgan","year":"2009","unstructured":"Morgan ET. Impact of infectious and inflammatory disease on cytochrome P450-mediated drug metabolism and pharmacokinetics. Clin Pharmacol Ther. 2009;85(4):434\u20138. https:\/\/doi.org\/10.1038\/clpt.2008.302.","journal-title":"Clin Pharmacol Ther"},{"issue":"8","key":"1318_CR19","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.autrev.2009.02.020","volume":"8","author":"C Perricone","year":"2009","unstructured":"Perricone C, De Carolis C, Perricone R. Glutathione: a key player in autoimmunity. Autoimmun Rev. 2009;8(8):697\u2013701. https:\/\/doi.org\/10.1016\/j.autrev.2009.02.020.","journal-title":"Autoimmun Rev"},{"issue":"5","key":"1318_CR20","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1038\/clpt.2011.35","volume":"89","author":"C Schmitt","year":"2011","unstructured":"Schmitt C, Kuhn B, Zhang X, Kivitz AJ, Grange S. Disease-drug-drug interaction involving tocilizumab and simvastatin in patients with rheumatoid arthritis. Clin Pharmacol Ther. 2011;89(5):735\u201340. https:\/\/doi.org\/10.1038\/clpt.2011.35.","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"1318_CR21","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1208\/s12248-023-00792-8","volume":"25","author":"V Purohit","year":"2023","unstructured":"Purohit V, Huh Y, Wojciechowski J, Plotka A, Salts S, Antinew J, et al. Leveraging prior healthy participant pharmacokinetic data to evaluate the impact of renal and hepatic impairment on ritlecitinib pharmacokinetics. AAPS J. 2023;25(3):32. https:\/\/doi.org\/10.1208\/s12248-023-00792-8.","journal-title":"AAPS J"},{"issue":"7","key":"1318_CR22","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.2215\/CJN.00340118","volume":"13","author":"TN Lea-Henry","year":"2018","unstructured":"Lea-Henry TN, Carland JE, Stocker SL, Sevastos J, Roberts DM. Clinical pharmacokinetics in kidney disease: fundamental principles. Clin J Am Soc Nephrol. 2018;13(7):1085\u201395. https:\/\/doi.org\/10.2215\/CJN.00340118.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1\u20133","key":"1318_CR23","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1159\/000321857","volume":"31","author":"AJ Olyaei","year":"2011","unstructured":"Olyaei AJ, Steffl JL. A quantitative approach to drug dosing in chronic kidney disease. Blood Purif. 2011;31(1\u20133):138\u201345. https:\/\/doi.org\/10.1159\/000321857.","journal-title":"Blood Purif"},{"issue":"4","key":"1318_CR24","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1111\/sdi.12374","volume":"28","author":"TD Nolin","year":"2015","unstructured":"Nolin TD. A synopsis of clinical pharmacokinetic alterations in advanced CKD. Semin Dial. 2015;28(4):325\u20139. https:\/\/doi.org\/10.1111\/sdi.12374.","journal-title":"Semin Dial"},{"key":"1318_CR25","unstructured":"Litfulo (ritlecitinib). Prescribing information. Pfizer. 2023. https:\/\/labeling.pfizer.com\/ShowLabeling.aspx?id=19638. Accessed 14 Aug 2023."}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-023-01318-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-023-01318-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-023-01318-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,28]],"date-time":"2023-11-28T14:16:38Z","timestamp":1701180998000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-023-01318-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,2]]},"references-count":25,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["1318"],"URL":"https:\/\/doi.org\/10.1007\/s40262-023-01318-3","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,2]]},"assertion":[{"value":"4 October 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 November 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was funded by Pfizer Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Jessica Wojciechowski, Vivek Purohit, Yeamin Huh, Christopher Banfield, and Timothy Nicholas are employees of and hold stock in Pfizer.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest\/Competing Interests"}},{"value":"The study protocols were approved by the Institutional Review Boards\/Ethics Committees of the study sites. The studies were conducted in compliance with the ethical principles originating in or derived from the Declaration of Helsinki and conducted according to the International Conference on Harmonization Guidelines for Good Clinical Practice.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"All participants provided written informed consent.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Upon request, and subject to review, Pfizer will provide the data that support the findings of this study. Subject to certain criteria, conditions, and exceptions, Pfizer may also provide access to the related individual de-identified participant data. See  for more information.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Wrote the manuscript: JW. Designed the research: JW, VSP, YH, CB, TN. Performed the research: JW, VSP, YH, CB. Analyzed the data: JW, VSP, YH, CB, TN.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}},{"value":"Consent to Publish. Patients signed informed consent regarding publishing their data.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}}]}}